Study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Catalent to support manufacturing for Galapagos’ GLPG5101

The CAR-T therapy is aimed at treating relapsed/refractory non-Hodgkin lymphoma. Credit: Chinnapong/Shutterstock. Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing in

January 22, 2025

Regeneron sues Sandoz to halt biosimilar to its blockbuster eye drug

Regeneron is going after Sandoz in a New Jersey federal court over Sandoz’s recently-approved drug Enzeevu, a biosimilar to Regeneron’s blockbuster eye treatment Eylea. …

August 29, 2024

Higher diet quality scores linked to lower emissions but come with trade-offs

Plant-based diets show the best sustainability outcomes, reducing emissions and land use, but increase water use and costs, highlighting diet trade-offs.

December 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.